ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis PigmentosaGlobeNewsWire • 12/11/19
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis PigmentosaGlobeNewsWire • 11/21/19
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 10/18/19
ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10GlobeNewsWire • 10/15/19
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 PatientsGlobeNewsWire • 10/10/19
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAOGlobeNewsWire • 10/07/19
ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis PigmentosaGlobeNewsWire • 09/09/19